Sunshine Biopharma Enters LNP Alliance for mRNA Macromolecule

Sunshine Biopharma, Inc., a pharmaceutical company researching life-saving medicines in oncology and antivirals, has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (LNP) companies to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.
 
The collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects.
 
The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology.
 
“We are delighted to be working with our new partner and their fully integrated team of experts in LNP technology,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.